Cabaletta Bio, Inc. (CABA) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-14

Key Insights

Rese-cel demonstrated compelling drug-free clinical responses in 2 of 4 lowest-dose patients with pemphigus vulgaris without preconditioning, with similar CAR T cell expansion kinetics to preconditioned patients, suggesting potential to broaden patient reach and reduce treatment burden.
Automated manufacturing using Cellares Cell Shuttle platform successfully replicated process consistency with first two GMP doses meeting all release specifications, supporting scalable commercial supply with minimal capital investment if approved.
Company expects additional data from higher PC-free doses in H2 2026 and initial RESET-SLE data in 1H 2026, providing near-term catalysts for clinical validation and potential expansion into other autoimmune indications beyond pemphigus vulgaris.

Want the newest filings?

This analysis covers the filing from 2026-05-14. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-05-14

Cabaletta Bio announced Q1 2026 financial results on May 14, 2026, with the full details provided in an attached press release that was furnished but not filed, limiting its regulatory weight.
The 8-K filing itself contains minimal substantive information, serving primarily as a vehicle to disclose earnings results rather than a material event or corporate action.
As a clinical-stage biotech company, investors should focus on the press release details regarding pipeline progress, cash position, and burn rate rather than the 8-K structure itself, which provides no operational insights.

Filed: 2026-03-23

Cabaletta Bio reported its Q4 2025 and full-year 2025 financial results, providing investors with an update on the company's financial performance and operational progress.
The company posted an updated corporate presentation, which likely contains new information on its pipeline, milestones, and strategic initiatives that investors should review.
Investors should monitor any potential changes in Cabaletta's leadership team or key personnel, as management transitions can impact a company's direction and execution.

Filed: 2026-01-12

Cabaletta Bio has initiated a registrational cohort for its rese-cel therapy in dermatomyositis and antisynthetase syndrome, which affects about 70,000 patients in the US, with the potential to submit a Biologics License Application next year.
The company has aligned with the FDA on registrational cohort designs for evaluating rese-cel in systemic lupus erythematosus and lupus nephritis, with updates expected later this year.
Cabaletta is advancing its fully automated, scalable manufacturing for rese-cel using Cellares' Cell Shuttle and Cell Q technology, which could enable rapid global expansion and lower manufacturing costs post-commercialization.

Other reports for Cabaletta Bio, Inc.

Quarterly Report Annual Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.